PDX-Derived Lung Cancer Organoid Model

Lung cancer is a refractory cancer that has become the leading cause of cancer death worldwide. When it metastasizes to other tissues from the lung, the most difficult phase to cure is coming. Due to the complexity of this disease, it’s urgent to seek new treatment strategies. At Creative Biolabs, we have made a real effort and achieved achievements by studying the 3D biology technologies such as PDX-derived lung cancer organoids to support our customers all over the world.

Shortcomings of Common Models

During the past years, cell lines are the most used model to study cancer. It’s no doubt that they can indeed mimic clinical drug responses in some cases. However, to our knowledge, those therapy strategies verified on cell lines tend to get disappointing results in phase III clinical trials as cell lines can’t show preserve tumor heterogeneity and show a limited capability to reveal the tumor complexity and drug responses. In recent years, patient-derived xenografts (PDXs) emerge and bring an unprecedented opportunity for lung cancer research. However, a variety of new issues arise and hinder the widespread application in preclinical research, for instance, expensive, time-consuming, and unsuitable for large-scale drug screening.

Advantages of PDX-derived Lung Cancer Organoid Models

After PDX models, the organoids come into being and gradually derive the PDX-derived lung cancer organoid models. Compared to the previous models, they are special and more universal to many experiments. Specific advantages can be summarized as follows.

• They can dynamically adapt to high-throughput drug screening platforms, study interactions between cancer and microenvironment, and be suitable for gene-editing techniques.
• Compared to 2D cell lines, they reproduce parental tumors’ heterogeneity from the genetic and histological features, and recapitulate tumor pathogenesis more faithfully.
• The PDX lung cancer organoids can be expanded and cryopreserved for a long time in vitro, but still have the differentiation ability.
• The whole procedure of lung cancer organoid (LCO) generation and testing takes less than two weeks, being more efficient than animal models.

Applications

Although LCO technology derived from PDX models is still in its infancy, the bright future is promising based on its powerful role in the lung cancer field currently. With extensive applicability, it has been widely applied in tumor biology, tumor environment, biobank establishment, and drug screening experiments, which will encourage scientists to perform a deeper exploration through basic and translational research on lung cancer.

Fig.1 Applications of LCOs in basic and translational lung cancer research. (Creative Biolabs)

Related Services

Since its foundation, Creative Biolabs keep full enthusiasm for the biology field and always pursue the most advanced biology technology. For the past few years, our research and development team has constantly constructed 3D organoid models involving multiple types of cancer. We treat every customer sincerely and take your project seriously. We are willing to offer the first-rate PDX-derived lung cancer organoid model and related services listed below to guarantee a smoother run of your preclinical project. For more details, please feel free to contact us.

Related Sections:

• Patient-Derived Organoid (PDO) Model
• PDX-Derived Organoid (PDXO) Tumor Model